|
Volumn 29, Issue 2, 1990, Pages 155-162
|
Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma: A randomized trial
a,b a,b a,b a,b a,b a,b a,b a,b a,b a,b a,b |
Author keywords
Advanced; Adverse effects; Anbibodies; Interferon; Liver enzymes; Medroxyprogesterone; Random allocation; Renal adenocarcinoma
|
Indexed keywords
ALPHA2A INTERFERON;
AMINOTRANSFERASE;
MEDROXYPROGESTERONE ACETATE;
RECOMBINANT ALPHA2A INTERFERON;
RECOMBINANT INTERFERON;
ADULT;
AGED;
ARTICLE;
CANCER CHEMOTHERAPY;
FATIGUE;
FEMALE;
HUMAN;
INTRAMUSCULAR DRUG ADMINISTRATION;
KIDNEY CARCINOMA;
LETHARGY;
MALE;
METHODOLOGY;
PRIORITY JOURNAL;
ADULT;
AGED;
CARCINOMA, RENAL CELL;
FEMALE;
HUMAN;
INTERFERON ALFA-2A;
INTERFERON TYPE I, RECOMBINANT;
KIDNEY NEOPLASMS;
LIVER;
MALE;
MEDROXYPROGESTERONE;
MIDDLE AGE;
RANDOMIZED CONTROLLED TRIALS;
|
EID: 0025247712
PISSN: 0284186X
EISSN: None
Source Type: Journal
DOI: 10.3109/02841869009126537 Document Type: Article |
Times cited : (80)
|
References (14)
|